Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population.
Tangri N, Ferguson T, Leon SJ, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Farjat AE, Farag YMK, Schloemer P, Lawatscheck R, Rohwedder K, Bakris GL. Tangri N, et al. Among authors: farjat ae. Clin Kidney J. 2024 Mar 6;17(4):sfae052. doi: 10.1093/ckj/sfae052. eCollection 2024 Apr. Clin Kidney J. 2024. PMID: 38650758 Free PMC article.
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
Bansal S, Canziani MEF, Birne R, Anker SD, Bakris GL, Filippatos G, Rossing P, Ruilope LM, Farjat AE, Kolkhof P, Lage A, Brinker M, Pitt B. Bansal S, et al. Among authors: farjat ae. BMJ Open. 2024 Mar 19;14(3):e076444. doi: 10.1136/bmjopen-2023-076444. BMJ Open. 2024. PMID: 38508632 Free PMC article. Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Among authors: farjat ae. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
Flack JM, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Adler SG, Fried L, Jamerson K, Toto R, Brinker M, Farjat AE, Kolkhof P, Lawatscheck R, Joseph A, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Flack JM, et al. Among authors: farjat ae. Kidney Med. 2023 Sep 28;5(12):100730. doi: 10.1016/j.xkme.2023.100730. eCollection 2023 Dec. Kidney Med. 2023. PMID: 38046911 Free PMC article.
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.
Turpie AGG, Farjat AE, Haas S, Ageno W, Weitz JI, Goldhaber SZ, Goto S, Angchaisuksiri P, Kayani G, Lopes RD, Chiang CE, Gibbs H, Tse E, Verhamme P, Ten Cate H, Muntaner J, Schellong S, Bounameaux H, Prandoni P, Maheshwari U, Kakkar AK; GARFIELD-VTE investigators. Turpie AGG, et al. Among authors: farjat ae. Thromb Res. 2023 Feb;222:31-39. doi: 10.1016/j.thromres.2022.11.016. Epub 2022 Nov 25. Thromb Res. 2023. PMID: 36565677 Free article.
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.
Haas S, Farjat AE, Pieper K, Ageno W, Angchaisuksiri P, Bounameaux H, Goldhaber SZ, Goto S, Mantovani L, Prandoni P, Schellong S, Turpie AGG, Weitz JI, MacCallum P, Cate HT, Panchenko E, Carrier M, Jerjes-Sanchez C, Gibbs H, Jansky P, Kayani G, Kakkar AK; GARFIELD-VTE investigators. Haas S, et al. Among authors: farjat ae. TH Open. 2022 Nov 3;6(4):e354-e364. doi: 10.1055/s-0042-1757744. eCollection 2022 Oct. TH Open. 2022. PMID: 36452204 Free PMC article.
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
Filippatos G, Anker SD, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D, Farjat AE, Kolkhof P, Scalise A, Joseph A, Bakris GL, Agarwal R. Filippatos G, et al. Among authors: farjat ae. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):85-93. doi: 10.1093/ehjcvp/pvac054. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 36251465 Free PMC article. Clinical Trial.
Corrigendum to "Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE" [Thromb. Res. 2021 May;201:63-72].
Angchaisuksiri P, Goto S, Farjat AE, Fryk H, Bang SM, Chiang CE, Jing ZC, Kondo K, Sathar J, Tse E, Phusanti S, Kayani G, Weitz JI, Ageno W, Goldhaber SZ, Kakkar AK. Angchaisuksiri P, et al. Among authors: farjat ae. Thromb Res. 2022 Jan;209:105. doi: 10.1016/j.thromres.2021.11.022. Epub 2021 Dec 15. Thromb Res. 2022. PMID: 34920389 No abstract available.
Corrigendum to "Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE" [Thromb. Res. 2020 Jul; 191:103-112].
Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Mantovani LG, Prandoni P, Kakkar AK. Bounameaux H, et al. Among authors: farjat ae. Thromb Res. 2022 Aug;216:129. doi: 10.1016/j.thromres.2021.11.023. Epub 2021 Dec 2. Thromb Res. 2022. PMID: 34863582 No abstract available.
Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE.
Cohen O, Ageno W, Farjat AE, Turpie AGG, Weitz JI, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. Cohen O, et al. Among authors: farjat ae. J Thromb Haemost. 2022 Feb;20(2):366-374. doi: 10.1111/jth.15574. Epub 2021 Nov 8. J Thromb Haemost. 2022. PMID: 34714962 Free PMC article.
45 results